Long-Term Side Effects of Allergy Shots: What the Evidence Shows

No evidence of cumulative organ damage has emerged across decades of SCIT surveillance and population registry studies. The most comprehensive data come from Linneberg 2012 (JACI), a Danish nationwide registry comparing SCIT-treated patients with those receiving conventional pharmacotherapy. Rather than organ damage, SCIT-treated patients showed lower rates of autoimmune disease, lower acute MI risk, and lower all-cause mortality. The 2011 AAAAI/ACAAI Practice Parameter Third Update specifically concluded that no new long-term safety signals had emerged with prolonged maintenance therapy. While long-term studies of any treatment have limitations, over 100 years of clinical SCIT use have not produced consistent signals of organ toxicity.

Current evidence does not support an increased cancer risk from allergy shots. Linneberg 2012 (JACI) found no increased mortality — including cancer mortality — in SCIT-treated patients versus matched controls. A 2021 systematic review by Larenas-Linnemann explicitly states that the historical contraindication of AIT in active malignancy is based on precautionary safety reasoning rather than evidence of SCIT causing or worsening cancer. No clear, consistent association between SCIT and cancer risk has been demonstrated in over a century of clinical use. Active malignancy remains a relative contraindication not because SCIT is known to promote cancer, but because treatment of newly diagnosed cancer takes precedence.

Clinical benefits from a completed allergy shot course typically persist for 3 to 12 years after stopping treatment, based on long-term follow-up studies. Durham et al. (N Engl J Med, 1999) demonstrated sustained clinical and immunological tolerance in grass-pollen SCIT patients 3 years after treatment ended, with significant benefit maintained versus controls. Eng et al. (2006) extended follow-up to 6 years post-treatment with continued benefit. Duration of post-treatment benefit scales with the length of treatment: patients completing the full 3-5 year course tend to maintain remission longer than those who stop early. Some patients experience gradual symptom return after many years and opt for a repeat course.

Some allergy shot formulations use aluminum hydroxide as an adjuvant to slow allergen absorption and prolong immune stimulation at the injection site. Over a typical 3-5 year SCIT course, cumulative aluminum exposure from injections has been estimated at approximately 10-50 mg — a range comparable to normal dietary aluminum intake over the same timeframe. Aluminum is ubiquitous in food, water, and cookware, and the body has well-established mechanisms for eliminating it renally. The primary documented complication of aluminum-containing depot extracts is formation of persistent itchy nodules at injection sites, a condition more common in European practice where depot formulations predominate. No systemic aluminum toxicity from SCIT has been confirmed in clinical studies.

Post-injection fatigue for hours to about 24 hours is widely acknowledged in allergy practice and is mechanistically consistent with transient cytokine release from late-phase immune responses — IL-1, IL-6, and TNF-alpha are well-established mediators of fatigue and sickness behavior. This tends to be more pronounced during build-up or after dose escalations. However, persistent fatigue lasting weeks or months and attributed specifically to SCIT is not systematically quantified in clinical trial data — this is a genuine evidence gap that current surveillance has not filled. If you are experiencing fatigue that lasts more than 24-48 hours after injections, or progressive fatigue over weeks, that warrants evaluation by your allergist to rule out other causes.

No withdrawal syndrome has been documented when allergy shots are discontinued after completing a full course. Unlike medications that cause physical dependence, SCIT works by inducing immunological tolerance — a trained state that does not produce rebound or withdrawal when treatment ends. What patients may experience is a gradual return of allergy symptoms over years as the immunological benefit wanes, particularly if the full 3-5 year course was not completed. This is not withdrawal — it is simply the natural course of the underlying allergy reasserting itself. Patients who completed full treatment courses tend to maintain remission significantly longer than those who stopped early.

Beta-blockers are a relative contraindication to continued SCIT because they impair epinephrine response — the first-line treatment for a systemic allergic reaction. If beta-blocker blockade is present and a severe reaction occurs, standard epinephrine doses are less effective, and glucagon (1-5 mg IV) becomes the rescue treatment. This is a case-by-case decision: the 2011 AAAAI/ACAAI Practice Parameter lists beta-blockers as a relative contraindication, while the 2023 Anaphylaxis Practice Parameter (Golden et al.) updated guidance toward shared decision-making when cardiac indications are compelling. You should inform your allergist immediately if you are prescribed beta-blockers, and explicitly discuss whether to continue, pause, or stop SCIT.